{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:36:09Z","timestamp":1788914169010,"version":"build-2803163510"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT108082AIA"],"award-info":[{"award-number":["WT108082AIA"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite expanded antiretroviral therapy (ART) in South Africa, HIV-1 transmission persists. Integrase strand transfer inhibitors (INSTI) and long-acting injectables offer potential for superior viral suppression, but pre-existing drug resistance could threaten their effectiveness. In a community-based study in rural KwaZulu-Natal, prior to widespread INSTI usage, we enroled 18,025 individuals to characterise HIV-1 drug resistance and transmission networks to inform public health strategies. HIV testing and reflex viral load quantification were performed, with deep sequencing (20% variant threshold) used to detect resistance mutations. Phylogenetic and geospatial analyses characterised transmission clusters. One-third of participants were HIV-positive, with 21.7% having detectable viral loads; 62.1% of those with detectable viral loads were ART-na\u00efve. Resistance to older reverse transcriptase (RT)-targeting drugs was found, but INSTI resistance remained low (&lt;1%). Non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance, particularly to rilpivirine (RPV) even in ART-na\u00efve individuals, was concerning. Twenty percent of sequenced individuals belonged to transmission clusters, with geographic analysis highlighting higher clustering in peripheral and rural areas. Our findings suggest promise for INSTI-based strategies in this setting but underscore the need for RPV resistance screening before implementing long-acting cabotegravir (CAB)\u2009+\u2009RPV. The significant clustering emphasises the importance of geographically targeted interventions to effectively curb HIV-1 transmission.<\/jats:p>","DOI":"10.1038\/s41467-024-47254-z","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T14:02:19Z","timestamp":1714399339000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["HIV transmission dynamics and population-wide drug resistance in rural South Africa"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7077-6793","authenticated-orcid":false,"given":"Steven A.","family":"Kemp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimia","family":"Kamelian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7060-4203","authenticated-orcid":false,"given":"Diego F.","family":"Cuadros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"PANGEA Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Vukuzazi Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4323-5574","authenticated-orcid":false,"given":"Mark T. K.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elphas","family":"Okango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3070-6154","authenticated-orcid":false,"given":"Willem","family":"Hanekom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thumbi","family":"Ndung\u2019u","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deenan","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bonsall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4755-5380","authenticated-orcid":false,"given":"Emily B.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tanser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3506-842X","authenticated-orcid":false,"given":"Mark J.","family":"Siedner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9751-1808","authenticated-orcid":false,"given":"Ravindra K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"key":"47254_CR1","unstructured":"HIV and AIDS Estimates - South Africa 2021. UNAIDS. (UNAIDS, 2022)."},{"key":"47254_CR2","unstructured":"G. H. collaborators. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980\u20132017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet HIV 6, e831\u2013e859 (2019)."},{"key":"47254_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.chom.2019.06.010","volume":"26","author":"DA Collier","year":"2019","unstructured":"Collier, D. A., Monit, C. & Gupta, R. K. The impact of HIV-1 drug escape on the global treatment landscape. Cell Host Microbe 26, 48\u201360 (2019).","journal-title":"Cell Host Microbe"},{"key":"47254_CR4","doi-asserted-by":"publisher","first-page":"e620","DOI":"10.1016\/S2352-3018(20)30172-7","volume":"7","author":"A Gupta-Wright","year":"2020","unstructured":"Gupta-Wright, A. et al. Virological failure, HIV-1 drug resistance, and early mortality in adults admitted to hospital in Malawi: an observational cohort study. Lancet HIV 7, e620\u2013e628 (2020).","journal-title":"Lancet HIV"},{"key":"47254_CR5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","volume":"18","author":"RK Gupta","year":"2018","unstructured":"Gupta, R. K. et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect. Dis. 18, 346\u2013355 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"47254_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S1473-3099(09)70136-7","volume":"9","author":"RK Gupta","year":"2009","unstructured":"Gupta, R. K. et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect. Dis. 9, 409\u2013417 (2009).","journal-title":"Lancet Infect. Dis."},{"key":"47254_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.eclinm.2019.03.006","volume":"9","author":"B Chimukangara","year":"2019","unstructured":"Chimukangara, B. et al. Trends in pretreatment HIV-1 drug resistance in antiretroviral therapy-naive adults in South Africa, 2000\u20132016: a pooled sequence analysis. EClinicalMedicine 9, 26\u201334 (2019).","journal-title":"EClinicalMedicine"},{"key":"47254_CR8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","volume":"16","author":"G TenoRes Study","year":"2016","unstructured":"TenoRes Study, G. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect. Dis. 16, 565\u2013575 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"47254_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1089\/aid.2019.0171","volume":"36","author":"M Boffito","year":"2020","unstructured":"Boffito, M. et al. Perspectives on the barrier to resistance for dolutegravir + lamivudine, a two-drug antiretroviral therapy for HIV-1 infection. AIDS Res. Hum. Retroviruses 36, 13\u201318 (2020).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"47254_CR10","doi-asserted-by":"crossref","unstructured":"Tao, K. et al. Treatment emergent dolutegravir resistance mutations in individuals naive to HIV-1 integrase inhibitors: a rapid scoping review. Viruses 15, 1932 (2023).","DOI":"10.3390\/v15091932"},{"key":"47254_CR11","unstructured":"Veronika, W. et al. VIROLOGIC FAILURE AFTER ROUTINE SWITCHING TO DTG-BASED FIRST-LINE ART. Conferernce on Retroviruses and Opportunistic Infections (CROI) 19\u201322, (Seattle, Washington, 2023)."},{"key":"47254_CR12","doi-asserted-by":"crossref","unstructured":"Loosli, T. et al. HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis. Lancet HIV 10, e733\u2013e741 (2023).","DOI":"10.1016\/S2352-3018(23)00228-X"},{"key":"47254_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19801-x","volume":"11","author":"MJ Siedner","year":"2020","unstructured":"Siedner, M. J. et al. Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase. Nat. Commun. 11, 5922 (2020).","journal-title":"Nat. Commun."},{"key":"47254_CR14","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1097\/QAD.0000000000003505","volume":"37","author":"K Steegen","year":"2023","unstructured":"Steegen, K., Chandiwana, N., Sokhela, S., Venter, W. D. F. & Hans, L. Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries. AIDS 37, 1009\u20131011 (2023).","journal-title":"AIDS"},{"key":"47254_CR15","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1126\/science.271.5253.1282","volume":"271","author":"MA Wainberg","year":"1996","unstructured":"Wainberg, M. A. et al. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 271, 1282\u20131285 (1996).","journal-title":"Science"},{"key":"47254_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1586\/14787210.2.1.147","volume":"2","author":"MA Wainberg","year":"2004","unstructured":"Wainberg, M. A. The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev. Anti-infect. Ther. 2, 147\u2013151 (2004).","journal-title":"Expert Rev. Anti-infect. Ther."},{"key":"47254_CR17","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1128\/JVI.02154-08","volume":"83","author":"R Paredes","year":"2009","unstructured":"Paredes, R. et al. In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J. Virol. 83, 2038\u20132043 (2009).","journal-title":"J. Virol."},{"key":"47254_CR18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ebiom.2017.03.024","volume":"18","author":"SY Rhee","year":"2017","unstructured":"Rhee, S. Y. et al. Mutational correlates of virological failure in individuals receiving a WHO-recommended tenofovir-containing first-line regimen: an International Collaboration. EBioMedicine 18, 225\u2013235 (2017).","journal-title":"EBioMedicine"},{"key":"47254_CR19","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/infdis\/jiz631","volume":"222","author":"J Gregson","year":"2020","unstructured":"Gregson, J. et al. Human immunodeficiency virus-1 viral load is elevated in individuals with reverse-transcriptase mutation M184V\/I during virological failure of first-line antiretroviral therapy and is associated with compensatory mutation L74I. J. Infect. Dis. 222, 1108\u20131116 (2020).","journal-title":"J. Infect. Dis."},{"key":"47254_CR20","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3018(22)00365-4","volume":"10","author":"J Smith","year":"2023","unstructured":"Smith, J. et al. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. Lancet HIV 10, e254\u2013e265 (2023).","journal-title":"Lancet HIV"},{"key":"47254_CR21","doi-asserted-by":"publisher","first-page":"e0208689","DOI":"10.1371\/journal.pone.0208689","volume":"13","author":"K Baisley","year":"2018","unstructured":"Baisley, K. et al. High HIV incidence and low uptake of HIV prevention services: the context of risk for young male adults prior to DREAMS in rural KwaZulu-Natal, South Africa. PLoS ONE 13, e0208689 (2018).","journal-title":"PLoS ONE"},{"key":"47254_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2989\/16085906.2017.1402793","volume":"17","author":"S Mottiar","year":"2018","unstructured":"Mottiar, S. & Lodge, T. The role of community health workers in supporting South Africa\u2019s HIV\/AIDS treatment programme. Afr. J. AIDS Res. 17, 54\u201361 (2018).","journal-title":"Afr. J. AIDS Res."},{"key":"47254_CR23","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1016\/S2352-3018(16)30224-7","volume":"4","author":"N Haber","year":"2017","unstructured":"Haber, N. et al. From HIV infection to therapeutic response: a population-based longitudinal HIV cascade-of-care study in KwaZulu-Natal, South Africa. Lancet HIV 4, e223\u2013e230 (2017).","journal-title":"Lancet HIV"},{"key":"47254_CR24","doi-asserted-by":"publisher","first-page":"e967","DOI":"10.1016\/S2214-109X(21)00176-5","volume":"9","author":"EB Wong","year":"2021","unstructured":"Wong, E. B. et al. Convergence of infectious and non-communicable disease epidemics in rural South Africa: a cross-sectional, population-based multimorbidity study. Lancet Glob. Health 9, e967\u2013e976 (2021).","journal-title":"Lancet Glob. Health"},{"key":"47254_CR25","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/S1473-3099(16)30469-8","volume":"17","author":"J Gregson","year":"2017","unstructured":"Gregson, J. et al. Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study. Lancet Infect. Dis. 17, 296\u2013304 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"47254_CR26","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.4102\/sajhivmed.v21i1.1115","volume":"21","author":"J Nel","year":"2020","unstructured":"Nel, J. et al. Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update. South Afr. J. HIV Med. 21, 1115 (2020).","journal-title":"South Afr. J. HIV Med."},{"key":"47254_CR27","doi-asserted-by":"publisher","first-page":"e0000826","DOI":"10.1371\/journal.pgph.0000826","volume":"2","author":"ENJ Semengue","year":"2022","unstructured":"Semengue, E. N. J. et al. HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis. PLoS Global Public Health 2, e0000826 (2022).","journal-title":"PLoS Global Public Health"},{"key":"47254_CR28","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1093\/cid\/cit933","volume":"58","author":"RK Gupta","year":"2014","unstructured":"Gupta, R. K. et al. High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy. Clin. Infect. Dis. 58, 1023\u20131026 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"47254_CR29","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1093\/jac\/dkad258","volume":"78","author":"D Maruapula","year":"2023","unstructured":"Maruapula, D. et al. Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir\/rilpivirine use. J. Antimicrob. Chemother. 78, 2489\u20132495 (2023).","journal-title":"J. Antimicrob. Chemother."},{"key":"47254_CR30","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","volume":"35","author":"AG Cutrell","year":"2021","unstructured":"Cutrell, A. G. et al. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis. AIDS 35, 1333\u20131342 (2021).","journal-title":"AIDS"},{"key":"47254_CR31","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S0140-6736(12)61038-1","volume":"380","author":"RK Gupta","year":"2012","unstructured":"Gupta, R. K. et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 380, 1250\u20131258 (2012).","journal-title":"Lancet"},{"key":"47254_CR32","doi-asserted-by":"crossref","unstructured":"Derache, A. et al. Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART. J. Antimicrob. Chemother. 74, 473\u2013479 (2019).","DOI":"10.1093\/jac\/dky428"},{"key":"47254_CR33","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1086\/381784","volume":"189","author":"MD Miller","year":"2004","unstructured":"Miller, M. D. et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J. Infect. Dis. 189, 837\u2013846 (2004).","journal-title":"J. Infect. Dis."},{"key":"47254_CR34","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/jac\/dkab385","volume":"77","author":"K El Bouzidi","year":"2022","unstructured":"El Bouzidi, K. et al. Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria. J. Antimicrob. Chemother. 77, 474\u2013482 (2022).","journal-title":"J. Antimicrob. Chemother."},{"key":"47254_CR35","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1097\/01.aids.0000189860.36688.e5","volume":"19","author":"RK Gupta","year":"2005","unstructured":"Gupta, R. K. et al. K65R and Y181C are less prevalent in HAART-experienced HIV-1 subtype A patients. AIDS 19, 1916\u20131919 (2005).","journal-title":"AIDS"},{"key":"47254_CR36","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/jac\/dkx091","volume":"72","author":"E Smit","year":"2017","unstructured":"Smit, E. et al. An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs. J. Antimicrob. Chemother. 72, 2075\u20132082 (2017).","journal-title":"J. Antimicrob. Chemother."},{"key":"47254_CR37","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1128\/AAC.01668-12","volume":"57","author":"K Theys","year":"2013","unstructured":"Theys, K. et al. HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. Antimicrob. Agents Chemother. 57, 1053\u20131056 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"47254_CR38","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1097\/QAD.0b013e328356886d","volume":"26","author":"H Sunpath","year":"2012","unstructured":"Sunpath, H. et al. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. AIDS 26, 1679\u20131684 (2012).","journal-title":"AIDS"},{"key":"47254_CR39","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1089\/aid.2011.0142","volume":"28","author":"MM Santoro","year":"2012","unstructured":"Santoro, M. M. et al. Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy. AIDS Res. Hum. Retroviruses 28, 1285\u20131293 (2012).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"47254_CR40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3851\/IMP1443","volume":"20","author":"D Coutsinos","year":"2010","unstructured":"Coutsinos, D., Invernizzi, C. F., Xu, H., Brenner, B. G. & Wainberg, M. A. Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1. Antivir. Chem. Chemother. 20, 117\u2013131 (2010).","journal-title":"Antivir. Chem. Chemother."},{"key":"47254_CR41","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1016\/S2352-3018(19)30400-X","volume":"7","author":"AN Phillips","year":"2020","unstructured":"Phillips, A. N. et al. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines. Lancet HIV 7, e193\u2013e200 (2020).","journal-title":"Lancet HIV"},{"key":"47254_CR42","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy329","volume":"6","author":"N Ahmed","year":"2019","unstructured":"Ahmed, N. et al. Development of the R263K mutation to dolutegravir in an HIV-1 subtype D virus harboring 3 class-drug resistance. Open Forum Infect. Dis. 6, ofy329 (2019).","journal-title":"Open Forum Infect. Dis."},{"key":"47254_CR43","first-page":"1575","volume":"75","author":"K El Bouzidi","year":"2020","unstructured":"El Bouzidi, K. et al. High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment. J. Antimicrob. Chemother. 75, 1575\u20131579 (2020).","journal-title":"J. Antimicrob. Chemother."},{"key":"47254_CR44","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1056\/NEJMc1806554","volume":"381","author":"N L\u00fcbke","year":"2019","unstructured":"L\u00fcbke, N. et al. Failure of dolutegravir first-line ART with selection of virus carrying R263K and G118R. N. Engl. J. Med. 381, 887\u2013889 (2019).","journal-title":"N. Engl. J. Med."},{"key":"47254_CR45","doi-asserted-by":"crossref","unstructured":"George, J. M. et al. Rapid development of high-level resistance to dolutegravir with emergence of T97A mutation in 2 treatment-experienced individuals with baseline partial sensitivity to dolutegravir. Open Forum Infect. Dis. 5, ofy221 (2018).","DOI":"10.1093\/ofid\/ofy221"},{"key":"47254_CR46","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1093\/jac\/dkad195","volume":"78","author":"A Abdullahi","year":"2023","unstructured":"Abdullahi, A. et al. Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort. J. Antimicrob. Chemother. 78, 2000\u20132007 (2023).","journal-title":"J. Antimicrob. Chemother."},{"key":"47254_CR47","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","volume":"399","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe, S. et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet 399, 1779\u20131789 (2022).","journal-title":"Lancet"},{"key":"47254_CR48","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz, R. J. et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N. Engl. J. Med. 385, 595\u2013608 (2021).","journal-title":"N. Engl. J. Med."},{"key":"47254_CR49","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s11904-022-00616-y","volume":"19","author":"UM Parikh","year":"2022","unstructured":"Parikh, U. M., Koss, C. A. & Mellors, J. W. Long-acting injectable cabotegravir for HIV prevention: what do we know and need to know about the risks and consequences of cabotegravir resistance? Curr. HIV\/AIDS Rep. 19, 384\u2013393 (2022).","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"47254_CR50","doi-asserted-by":"publisher","first-page":"e0000105","DOI":"10.1371\/journal.pgph.0000105","volume":"2","author":"DF Cuadros","year":"2022","unstructured":"Cuadros, D. F. et al. The role of high-risk geographies in the perpetuation of the HIV epidemic in rural South Africa: a spatial molecular epidemiology study. PLoS Glob. Public Health 2, e0000105 (2022).","journal-title":"PLoS Glob. Public Health"},{"key":"47254_CR51","doi-asserted-by":"crossref","unstructured":"McCoy, S. I. & Packel, L. Lessons from early stage pilot studies to maximize the impact of digital health interventions for sexual and reproductive health. Mhealth 6, 22 (2020).","DOI":"10.21037\/mhealth.2020.02.03"},{"key":"47254_CR52","doi-asserted-by":"publisher","first-page":"e0260555","DOI":"10.1371\/journal.pone.0260555","volume":"16","author":"G Ayala","year":"2021","unstructured":"Ayala, G. et al. Peer-and community-led responses to HIV: a scoping review. PLoS ONE 16, e0260555 (2021).","journal-title":"PLoS ONE"},{"key":"47254_CR53","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11684-020-0756-y","volume":"14","author":"X Han","year":"2020","unstructured":"Han, X., Zhao, B., An, M., Zhong, P. & Shang, H. Molecular network-based intervention brings us closer to ending the HIV pandemic. Front. Med. 14, 136\u2013148 (2020).","journal-title":"Front. Med."},{"key":"47254_CR54","unstructured":"WHO. Sentinel Surveys of Acquired HIV Resistance to Dolutegravir Among People Receiving Dolutegravir-containing Antiretroviral Therapy (WHO, 2023)."},{"key":"47254_CR55","doi-asserted-by":"publisher","DOI":"10.1140\/epjds\/s13688-021-00261-2","volume":"10","author":"C Zhao","year":"2021","unstructured":"Zhao, C., Zeng, A. & Yeung, C. H. Characteristics of human mobility patterns revealed by high-frequency cell-phone position data. EPJ Data Sci. 10, 5 (2021).","journal-title":"EPJ Data Sci."},{"key":"47254_CR56","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/095632020401500302","volume":"15","author":"Z Zhang","year":"2004","unstructured":"Zhang, Z., Hamatake, R. & Hong, Z. Clinical utility of current NNRTIs and perspectives of new agents in this class under development. Antiviral Chem. Chemother. 15, 121\u2013134 (2004).","journal-title":"Antiviral Chem. Chemother."},{"key":"47254_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09464-y","volume":"7","author":"DF Cuadros","year":"2017","unstructured":"Cuadros, D. F. et al. Mapping the spatial variability of HIV infection in Sub-Saharan Africa: effective information for localized HIV prevention and control. Sci. Rep. 7, 9093 (2017).","journal-title":"Sci. Rep."},{"key":"47254_CR58","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1007\/s10461-018-2166-6","volume":"22","author":"D Panagiotoglou","year":"2018","unstructured":"Panagiotoglou, D. et al. Building the case for localized approaches to HIV: structural conditions and health system capacity to address the HIV\/AIDS epidemic in six US cities. AIDS Behav. 22, 3071\u20133082 (2018).","journal-title":"AIDS Behav."},{"key":"47254_CR59","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00269-22","volume":"13","author":"SA Kemp","year":"2022","unstructured":"Kemp, S. A. et al. HIV-1 evolutionary dynamics under nonsuppressive antiretroviral therapy. mBio 13, e0026922 (2022).","journal-title":"mBio"},{"key":"47254_CR60","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1093\/ije\/dyab229","volume":"51","author":"R Gunda","year":"2022","unstructured":"Gunda, R. et al. Cohort Profile: the Vukuzazi (\u2018wake up and know yourself\u2019 in isiZulu) population science programme. Int. J. Epidemiol. 51, e131\u2013e142 (2022).","journal-title":"Int. J. Epidemiol."},{"key":"47254_CR61","doi-asserted-by":"crossref","unstructured":"Bonsall, D. et al. A Comprehensive genomics solution for HIV surveillance and clinical monitoring in low-income settings. J. Clin. Microbiol. 58, e00382-20 (2020).","DOI":"10.1128\/JCM.00382-20"},{"key":"47254_CR62","doi-asserted-by":"crossref","unstructured":"Susvitasari, K. et al. Epidemiological cluster identification using multiple data sources: an approach using logistic regression. Microb. Genom. 9, mgen000929 (2023).","DOI":"10.1099\/mgen.0.000929"},{"key":"47254_CR63","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/molbev\/msx304","volume":"35","author":"C Wymant","year":"2018","unstructured":"Wymant, C. et al. PHYLOSCANNER: inferring transmission from within-and between-host pathogen genetic diversity. Mol. Biol. Evol. 35, 719\u2013733 (2018).","journal-title":"Mol. Biol. Evol."},{"key":"47254_CR64","doi-asserted-by":"crossref","unstructured":"Waller, L. A. & Gotway, C. A. Applied Spatial Statistics for Public Health Data (John Wiley & Sons, 2004).","DOI":"10.1002\/0471662682"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-47254-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-47254-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-47254-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T14:03:48Z","timestamp":1714399428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-47254-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["47254"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-47254-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3640717\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]},"assertion":[{"value":"20 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.K.G. has received honoraria from ViiV and Gilead for advisory board participation. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3644"}}